PML and AURKA

  • Number of citations of the paper that reports this interaction (PMID 15749021)
  • 13
  • Data Source:
  • BioGRID (affinity chromatography technology)
  • HPRD (in vivo)

PML

AURKA

Gene Name promyelocytic leukemia aurora kinase A
Image
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
Protein-Protein Interactions 101 interactors: ADH1B ANKRD2 ARID3A ARNT ATF2 ATXN1 AURKA AXIN1 BANP BCL2 BCL6 CASP8AP2 CCNT1 CDK1 CDK2 CDK6 CHFR CREBBP CSNK2A1 DAXX EGFR EIF4E ELF4 EP300 FOS GATA2 HDAC1 HDAC2 HDAC3 HHEX HIPK2 HTT KAT5 KAT6A MAPK11 MAPK14 MDM2 MED7 MXD1 MYB MYC NCOA2 NCOR1 NCOR2 NFKB1 NR3C1 NR4A1 PAWR PAXIP1 PCBD2 PIAS1 PIAS2 PIN1 PLAGL1 PLSCR1 POLR2E PPARG PSMA3 RARA RB1 RBX1 RELA RNF111 RNF125 RNF4 RPL11 RXRA SENP2 SH3GL1 SIAH2 SIN3A SIRT1 SKI SMAD3 SP1 SP100 SRF STAT3 SUMO1 SUMO2 SUMO3 SUV39H1 SYNE2 TDG TERF2IP TGFBR1 TGFBR2 TGIF1 THRA TOPBP1 TP53 TP63 TP73 TRIM24 TRIM27 TRIM69 UBE2I UBE2U UBE3A ZBTB16 ZFYVE9 54 interactors: APP ARPC1B ARPC2 AURKAIP1 BIRC5 BORA BRCA1 CBX3 CDC20 CDC25B CHFR CKAP5 CSN2 GADD45A GMNN GSK3B HDAC2 HDAC6 HIST3H3 IKBKB INCENP KIF11 KIF2C MAPRE2 MAPRE3 MBD3 MDM2 NDC80 NFKBIA NIN NME1 NUF2 PLK3 PML PPP1CA PPP1CB PPP1CC PRKACA PTTG1 PUM2 RASSF1 SRPK1 SRPK2 SUMO1 TACC1 TACC3 TLK1 TLK2 TP53 TP73 TPX2 UBE2N USP2 VHL
Entrez ID 5371 6790
HPRD ID 00023 04066
Ensembl ID ENSG00000140464 ENSG00000087586
Uniprot IDs P29590 O14965
PDB IDs 1BOR 1MQ4 1MUO 1OL5 1OL6 1OL7 2BMC 2C6D 2C6E 2DWB 2J4Z 2J50 2NP8 2W1C 2W1D 2W1E 2W1F 2W1G 2WQE 2WTV 2WTW 2X6D 2X6E 2X81 2XNE 2XNG 2XRU 3COH 3E5A 3EFW 3FDN 3H0Y 3H0Z 3H10 3HA6 3K5U 3LAU 3M11 3MYG 3NRM 3O50 3O51 3P9J 3QBN 3R21 3R22 3UNZ 3UO4 3UO5 3UO6 3UOD 3UOH 3UOJ 3UOK 3UOL 3UP2 3UP7 3VAP 4B0G 4DEA 4DEB 4DED 4DEE 4DHF 4JAI 4JAJ 4JBO 4JBP 4JBQ
Enriched GO Terms of Interacting Partners?
Tagcloud ?
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
adenosine  ags  alisertib  als  ampk  antiapoptotic  aurora  autophagy  bioavailable  cip1  cytochrome  dependently  exerts  inducing  killing  kip1  mitochondria  monophosphate  n78  nci  orally  phosphatidylinositol  proapoptotic  proautophagic  responds  sb202191  threonine  waf1  wortmannin 
Tagcloud (Difference) ?
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
adenosine  ags  alisertib  als  ampk  antiapoptotic  aurora  autophagy  bioavailable  cip1  cytochrome  dependently  exerts  inducing  killing  kip1  mitochondria  monophosphate  n78  nci  orally  phosphatidylinositol  proapoptotic  proautophagic  responds  sb202191  threonine  waf1  wortmannin 
Tagcloud (Intersection) ?